About Aeglea Biotherapeutics
Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer.
State of Ownership
Chief Product Officer, Zapnito
CEO & Co-Founder, Zapnito
Sales Account Executive, Springer Nature